[10] Alzahrani, W.S., Bahkali, S.A., Alharthy, R.F., Alsabban, A.S., (2025)
Dapagliflozin plus exenatide on patients with type 2 diabetes awaiting bariatric surgery in the DEXBASU study
The company has 100 providers on staff, and most are certified in obesity medicine, Kantor said
The European Medicines Agency (EMA) and MHRA continue to monitor post-marketing safety data, which may provide more information about real-world use in diverse patient populations, including those with autoimmune conditions
doi: 10.1161/ATVBAHA.112.246207 50 WegebergA-MLHansenCSFarmerADKarmisholtJSDrewesAMJakobsenPEet al
This article explores the safety considerations, monitoring requirements, and alternative options for lupus patients considering Wegovy, emphasising the importance of coordinated care between rheumatology and weight management specialists to ensure safe, individualised treatment decisions